XNCR News and Press, Xencor Inc. From 11/22/20

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory di...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb ® bispecific antibody programs and...

-- XmAb20717 was generally well-tolerated; 19% objective response rate (ORR) observed across cohorts at the recommended dose level -- -- Early clinical activity, including prostate-specific antigen (PSA) reductions in patients with advanced prostate cancer, support initiation of new...

Xencor Inc (XNCR) Q3 2020 Earnings Conference Call November 05, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer Conference Call Partici...

Image source: The Motley Fool. Xencor Inc (NASDAQ: XNCR) Q3 2020 Earnings Call Nov 5, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Xencor Inc (XNCR) Q3 2020 Earnings Call Transcript

-- Management to Host Conference Call at 4:30 p.m. EST Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that data from the ongoing Phase 1 dose-escalation study of vibecotamab (XmAb ® 14045), a CD123...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after the market closes on Thursday, November...